| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 04/20/2006 | WO2006042263A2 Phosphoprotein affinity resins and methods for making and using the same |
| 04/20/2006 | WO2006042249A2 Methods and compositions for treating migraine pain |
| 04/20/2006 | WO2006042197A2 Use of del-1 in hair, bone and cartilage regeneration |
| 04/20/2006 | WO2006042152A2 Vasoactive intestinal polypeptide pharmaceuticals |
| 04/20/2006 | WO2006042151A2 Analogs of shk toxin and their uses in selective inhibition of kv1.3 potassium channels |
| 04/20/2006 | WO2006042017A2 Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
| 04/20/2006 | WO2006042002A2 Compositions and methods for treating disease |
| 04/20/2006 | WO2006041835A2 Methods of inhibiting cell death or inflammation in a mammal |
| 04/20/2006 | WO2006041829A2 Antagonist peptides to the c5a chemotactic function of vitamin d binding protein |
| 04/20/2006 | WO2006041631A2 Novel cyclosporin alkynes and their utility as pharmaceutical agents |
| 04/20/2006 | WO2006041488A1 Immortalized hepatocytes |
| 04/20/2006 | WO2006041205A1 Angiogenesis promoter |
| 04/20/2006 | WO2006041192A1 Medicinal compositions containing apoptosis inducer |
| 04/20/2006 | WO2006041120A1 Pharmaceutical composition |
| 04/20/2006 | WO2006041048A1 Liver regeneration/repair controlling agent |
| 04/20/2006 | WO2006040980A1 Lecithinized superoxide dismutase composition and process for producing the same |
| 04/20/2006 | WO2006040574A2 Lipocalin protein |
| 04/20/2006 | WO2006040481A2 Method for diagnosing and treating crohn's disease |
| 04/20/2006 | WO2006040374A1 Synthetic peptides which reduce or eliminate bags formed under the lower rim of the eyes and use thereof in cosmetic or dermopharmaceutical compositions |
| 04/20/2006 | WO2006040157A1 Anti-angiogenic peptide |
| 04/20/2006 | WO2006040114A1 Use of organic compounds |
| 04/20/2006 | WO2006040047A2 Diagnostics and therapeutics for diseases associated with rho/rac-interacting citron kinase (cit) |
| 04/20/2006 | WO2006021335A3 Peptide mixture from peptides having a molecular weight of from 1000 to 5000 dalton |
| 04/20/2006 | WO2006009838A3 Mycobacterium tuberculosis epitopes and methods of use thereof |
| 04/20/2006 | WO2006005912A3 Use of botulinum toxin for the preparation of a medicament for the treatment of lithiasis of salivary gland, gall bladder, kidney, or pancreas |
| 04/20/2006 | WO2005123115A8 Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants |
| 04/20/2006 | WO2005120588A3 Peptides delivered to cell nuclei |
| 04/20/2006 | WO2005117939A9 Use of gpcr54 ligands for the treatment of infertility |
| 04/20/2006 | WO2005117537A3 Peptide-based carbon nanotube hair colorants and their use in hair colorant and cosmetic compositions |
| 04/20/2006 | WO2005112984A3 Apparatus and method for transdermal delivery of parathyroid hormone agents |
| 04/20/2006 | WO2005112969A3 Herstatin or intron 8-encoded domain thereof for modulating signaling mediated by igf-1 receptor and erbb receptors |
| 04/20/2006 | WO2005087255A3 Method of optimizing treatment with interferon-tau |
| 04/20/2006 | WO2005085867A3 Screening method for emulators of neural activity and digestive system using gpr35 |
| 04/20/2006 | WO2005066371A3 Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
| 04/20/2006 | WO2005047314A3 Fgf-beta binding and supported peptides |
| 04/20/2006 | WO2004108088A3 Methods and compositions for interferon therapy |
| 04/20/2006 | WO2004071420A3 Compositions and methods for less immunogenic protein formulations |
| 04/20/2006 | WO2004064732A3 The use of bacterial phage-associated lysing proteins for preventing and treating bacterial infections in humans, animals and fowl |
| 04/20/2006 | WO2004044164A3 Method for identifying risk of melanoma and treatments thereof |
| 04/20/2006 | WO2004044011A3 Combinatorial libraries of monomer domains |
| 04/20/2006 | WO2003104401A3 Cancer-linked gene as target for chemotherapy |
| 04/20/2006 | WO2003047514A3 Reducing myelin-mediated inhibition of axon regeneration |
| 04/20/2006 | US20060084797 High affinity TGFbeta nucleic acid ligands and inhibitors |
| 04/20/2006 | US20060084793 G-CSF polypeptides and conjugates |
| 04/20/2006 | US20060084789 Immunotherapeutic and immunoprphylactic reagents |
| 04/20/2006 | US20060084697 Pi3k antagonists as radiosensitizers |
| 04/20/2006 | US20060084617 Methods for delivery of nucleic acids |
| 04/20/2006 | US20060084613 Dipeptide enzyme inhibitor; antiinflammatory agents; autoimmune disease; wound healing agents |
| 04/20/2006 | US20060084612 Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors |
| 04/20/2006 | US20060084611 Apoptotic compounds |
| 04/20/2006 | US20060084610 Peptides and peptidomimetics having anti-proliferative activity and/or that augment nucleic acid damaging agents or treatments |
| 04/20/2006 | US20060084609 Synthetic HLA binding WT-1 peptide analogues and uses thereof |
| 04/20/2006 | US20060084608 Binding polypeptides and methods based thereon |
| 04/20/2006 | US20060084607 Purified amphiphilic peptide compositions and uses thereof |
| 04/20/2006 | US20060084606 administering aromatic cationic peptide for specifically target mitochondria; ischemia is due to stroke, sepsis, inflammatory process, arthritis, diabetes, liver disorders, viral infection, to a removed organ |
| 04/20/2006 | US20060084605 Stable pharmaceutical compositions |
| 04/20/2006 | US20060084604 disclosed for the treatment of diabetes and related diseases using peptides with incretin hormone activity. Preferably, the peptide with incretin hormone activity is GLP-1, exendin or an analog of GLP-1 or exendin. The peptides with incretin hormone activity are administered transepithelially hormones |
| 04/20/2006 | US20060084603 IGF-BP3-related methods for inhibiting tumor growth |
| 04/20/2006 | US20060084602 Platelet-derived growth factor compositions and methods of use thereof |
| 04/20/2006 | US20060084601 Method for treating respiratory distress syndrome |
| 04/20/2006 | US20060084600 Human homologues of fused gene |
| 04/20/2006 | US20060084599 Compositions, methods and kits relating to notch signaling |
| 04/20/2006 | US20060084598 Administering to the patient about 15 to about 360 mg of alpha-1-antitrypsin per kg patient body mass, and repeating the administration at least once with a periodicity of between 3 and 31 days |
| 04/20/2006 | US20060084597 Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity |
| 04/20/2006 | US20060084596 Administering a biodrug comprising a growth factor binding compounds having a central non-peptide organic scaffold, such as a calix[4]arene, to which arelinked cyclic tetrapeptides; angiogenesis inhibiters; antitumor agents; solid tumors;anticarciogenic agents; restenosis |
| 04/20/2006 | US20060084595 Complex comprising OCIF and polysaccharide |
| 04/20/2006 | US20060084594 Therapy with clostridium perfringens enterotoxin to treat ovarian and uterine cancer |
| 04/20/2006 | US20060084593 Anti-hiv composition, production method thereof and medicament |
| 04/20/2006 | US20060084592 Peptide boronic acid inhibitors |
| 04/20/2006 | US20060084591 Use of modulators of the signal transduction path using the protein kinase fyn for the treatment of tumorous diseases |
| 04/20/2006 | US20060084590 Methods of and compounds for modulating the activity of bacterial FabG |
| 04/20/2006 | US20060084588 Modulation of immune function |
| 04/20/2006 | US20060084148 April-a novel protein with growth effects |
| 04/20/2006 | US20060084144 Genetic engineering; oligonucleotide detector; identification and isolation of novel DNA; transmembrane domain-deleted or transmembrane domain-inactivated protein; soluble extracellular domains; PRO polypeptide |
| 04/20/2006 | US20060084143 Screen for agonists and antagonists; treat solid tumors, vascular deficiencies; polypeptide, polynucleotide, plasmid; chemotherapeutic agents, alkylating agents, antimetabolites, vinca alkaloids, plant extracts, nitrosoureas, topoisomerase inhibitors, platinum analogs, adrenocortical suppressants |
| 04/20/2006 | US20060084142 tyrosine kinase; screening for inhibitors of PDGFRA; gastrointestinal stromal tumor (GIST) |
| 04/20/2006 | US20060084140 Polynucleotide encoding a novel human G-protein coupled receptor, HGPRBMY39 |
| 04/20/2006 | US20060084139 Genetic engineering; oligonucleotide detector; identification and isolation of novel DNA; transmembrane domain-deleted or transmembrane domain-inactivated protein; soluble extracellular domains; PRO polypeptide |
| 04/20/2006 | US20060084138 Genetic engineering; oligonucleotide detector; identification and isolation of novel DNA; transmembrane domain-deleted or transmembrane domain-inactivated protein; soluble extracellular domains; PRO polypeptide |
| 04/20/2006 | US20060084137 Coagulation, mechanical agitation; filtration |
| 04/20/2006 | US20060084129 Biosynthesis of lipid class metabolites from pathways of phosphatidylethanolamine-N-methyltransferase, CDP-choline, phosphatidylserine decarboxylase, CDP-ethanolamine or phosphatidylcholine; determining contribution of Acyl-CoA:cholesterol acyltransferase (ACAT) to biosynthesis of cholesterol ester |
| 04/20/2006 | US20060084121 OX2 receptor homologs |
| 04/20/2006 | US20060084119 Preparing budding virus expressing mammalian transporter having transporter activity by culturing host cell infected with budding virus comprising gene encoding transporter and is recombinantly expressing transporter, expressing transporter on envelope of budding virus released from host cell, harvesting |
| 04/20/2006 | US20060084118 Lymphocytes; transcription factors; interferons; diagnosis of autoimmune disease such as lupus |
| 04/20/2006 | US20060084109 Regulated aptamer therapeutics |
| 04/20/2006 | US20060084107 Methods of treating skin conditions using inhibitors of the CD2/LFA-3 interaction |
| 04/20/2006 | US20060084091 Methods and compositions for polypeptide engineering |
| 04/20/2006 | US20060084090 Modulation of interaction between Nod1 and Gram-negative bacteria by Nod1 response to peptidoglycan delivered by the Helicobacter pylori cag pathogenicity island (cagPAI) |
| 04/20/2006 | US20060084086 Proteins, polynucleotides encoding them and methods of using the same |
| 04/20/2006 | US20060084061 Methods for blocking adipocyte differentiation and triglyceride accumulation with interleukin 12 p35 inhibitors |
| 04/20/2006 | US20060083796 Orally administrable composition for improving hair and coat quality |
| 04/20/2006 | US20060083757 Method for treating cardiac muscle disorders |
| 04/20/2006 | US20060083754 Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases |
| 04/20/2006 | US20060083752 Novel compounds |
| 04/20/2006 | US20060083751 Therapeutic agents |
| 04/20/2006 | US20060083749 Compositions and methods for the therapy and diagnosis of breast cancer |
| 04/20/2006 | US20060083746 Receptor for B. anthracis toxin |
| 04/20/2006 | US20060083742 Prenyl-electrostatic switch, and methods of use |
| 04/20/2006 | US20060083740 By modulating the expression of mutant and wild type CD83 gene products produced in a mammal; regulation of T cell and dendritic cell activity; antibodies |
| 04/20/2006 | US20060083737 Intracellular peptide delivery |